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 ABSTRACT 
The protein Lin28 and microRNA let-7 play critical roles in mammalian development and 
human disease. Lin28 inhibits let-7 biogenesis through a direct interaction with let-7 
precursors (pre-let-7). Accumulating evidence in vitro and in vivo suggests this interaction 
plays a dominant role in embryonic stem cell self-renewal and tumorigenesis. Thus the Lin28-
let-7 interaction might be an attractive drug target, if not for the well-known difficultly in 
targeting protein-RNA interactions with drugs. The identification and development of suitable 
probe molecules to further elucidate therapeutic potential, as well as mechanistic details of 
this pathway will be valuable. We report the development and application of a biophysical 
high-throughput screening assay for the identification of small molecule inhibitors of the 
Lin28-pre-let-7 interaction. A library of pharmacologically active small molecules was 
screened and several small molecule inhibitors were identified and biochemically validated. 
Of these four validated inhibitors, two compounds successfully restored processing of pre-let-
7g in the presence of Lin28, validating the concept.  Thus, we have identified examples of 
small molecule inhibitors of the interaction between Lin28 and pre-let-7. This study provides 
a proof of concept for small molecule inhibitors that antagonise the effects of Lin28 and 
enhance processing of a let-7 miRNA. 
 
 
 
  
 INTRODUCTION 
Studies in vitro and in vivo have generated compelling data to support the role of the micro-
ribonucleic acid (miRNA) let-7 (Lethal 7) as a bona fide tumour suppressor gene, consistent 
with its involvement in regulating cell proliferation and differentiation1-3. The biogenesis of 
specific members of the let-7 family of miRNAs is inhibited by the pluripotency factor, 
human abnormal cell lineage protein 28 (Lin28), predominantly at the Dicer processing step, 
in both embryonic stem cells (ESC) and embryonic carcinoma cells4-6. This inhibition is 
mediated by direct interactions between Lin28 and the let-7 precursor (pre-let-7)7-9, and has 
been suggested to be the result of a consequent combination of RNA structural changes10-12, 
steric effects6, 10, 11, 13 and uridylation14-17. Lin28 assembles in a stepwise manner on pre-let-7 
to form a stable multimeric complex10, 13. Observation of the lower stoichiometric Lin28-pre-
let-7 complexes is dependent on the concentration of Lin28 and the presence of competitor 
RNAs10, 13. Mapping studies investigating complex formation using a variety of biophysical 
and biochemical methods13 coincide remarkably well with RNase protection studies reported 
by our group10; here two motifs in the pre-let-7 terminal loop were required for Lin28 
binding. Such interactions were responsible for destabilization of Watson–Crick base pairs 
within the terminal loop10, 13 and consequently capable of inhibiting dicer processing of pre-
let-710. Lin28 itself is involved in a variety of let-7-dependent and independent cellular 
processes; examples include cellular reprogramming18-23, proliferation20, 24, skeletal 
myogenesis25, glucose metabolism26, neurogliogenesis6, 27 and tumorigenesis28-31. Lin28 is 
thought to act as an oncogene at least in part due to its role in the suppression of specific 
members of the let-7 family28, 32-34. For example, a terminal loop mutant of pre-let-7g and a 
loopmiR targeting the pre-let-7a-1 terminal loop, both capable of directing pre-let-7 away 
from a Lin28-mediated Dicer processing block, were shown to reverse Lin28-directed cellular 
transformation28, 35. These observations suggest that the LIN28-let-7 interaction might be an 
 attractive target for conventional small molecule therapies; however, the well-known 
difficulties in targeting RNA-protein interactions with small molecules30, 31  hamper validation 
of this hypothesis. Small molecule probes capable of restoring the levels of let-7 miRNAs 
through inhibition of the Lin28-pre-let-7 interaction would be powerful tools for assessment 
of its potential as a novel target in human disease, as well as for further elucidation of this 
pathway. 
We describe the development and validation of a fluorescence polarization (FP) based assay 
for high-throughput screening of modulators of the Lin28-pre-let-7g interaction. A library of 
2768 pharmacologically active small molecules, including FDA approved drugs, was 
screened and several small molecule inhibitors of the interaction between Lin28 and pre-let-
7g were identified. Furthermore, two of the active molecules successfully restored Dicer 
processing of pre-let-7g in the presence of the inhibitor, Lin28, validating the overall 
approach.  
MATERIALS AND METHODS 
Fluorescence polarisation (FP) measurements 
All FP measurements were carried out in a 384-well, low-volume, black round-bottom 
polystyrene non-binding surface (NBS) micro-plate (Corning) using a PHERAstar Plus (BMG 
LABTECH) device. The plate reader was set in polarisation mode with 485 nm and 520 nm 
excitation and emission filters, respectively. Polarisation was measured and displayed in 
millipolarisation units (mP). The gain was adjusted for channel 1 and 2 using fluorescein 
(1 µM) in 50 mM Tris pH 7.5 such that an mP value of ~35 was obtained.  
Small molecule preparation 
Small molecules were obtained from Sigma Aldrich (LOPAC1280 library), the National 
Cancer Institute (NCI, NCI diversity set II) and an in-house library of the Prof. Shankar 
Balasubramanian laboratory. The small molecules were prepared at a concentration of 2 mM 
 in dimethyl sulfoxide (100% DMSO) and aliquoted into 384 Well Clear Round Bottom 
storage plates (Corning). The plates were stored at -80 ºC before and between uses. Prior to 
use in the screening protocol the small molecules were diluted to 100 µM in 1X binding 
buffer (50 mM Tris pH 7.5, 100 mM NaCl, 1 mM MgCl2). 
Small molecule screening protocol  
All solutions were dispensed using a Biomek® FXp liquid dispensing robot (Beckman 
Coulter). Wells were defined as follows: negative control (FAUtpre-let-7g/Lin28), samples 
(FAUtpre-let-7g/Lin28/small molecules), positive control 1 (FAUtpre-let-7g/Lin28/unlabeled 
tpre-let-7g) and positive control 2 (FAUtpre-let-7g). A solution of pre-mixed recombinant 
human Lin28 (0.300 µM) and FAUtpre-let-7g (fluorescein modified tpre-let-7g) (0.017 µM) 
in 1X binding buffer was distributed to sample, negative control, and positive control 1 well. 
FAUtpre-let-7g alone (0.017 µM) was added to the positive control 2 well. Small molecules 
(100 µM, 1X binding buffer, 5vol% DMSO) were added to the sample wells and binding 
buffer/DMSO (1X binding buffer, 5vol% DMSO) was added to the positive control 2 wells. 
Unlabeled tpre-let-7g (5vol% DMSO, 1X binding buffer) was added to positive control 1 
wells and used as a positive control competitor. The final concentrations of small molecule 
and unlabeled tpre-let-7g were 20 µM and 0.170 µM, respectively. DMSO was present at 
1vol% in all wells. Total volume of each reaction well was 20 µL. Screening plates were 
incubated for 20 min at room temperature (RT) prior to FP measurement. FP measurements 
were taken at 5 min intervals over 25 min. A hit was defined as a small molecule that reduced 
the change in FP between the negative and positive controls by 50%. All primary hits were 
repeated in triplicate. Reproducible primary hits were referred to as secondary hits. 
Conditions described above were applied in all assay development steps, with substitutions of 
Lin28 for GST, FAUtpre-let-7g for fluorescein and unlabeled tpre-let-7g for alternative RNAs 
(C/A pre-let-7g mutant and total yeast RNA). 
Electrophoretic Mobility Shift Assay (EMSA) 
 The secondary hits identified were tested against the full-length pre-let-7g-Lin28 interaction 
in an EMSA. Small molecules (100 µM, 1X binding buffer, 5vol% DMSO), binding 
buffer/DMSO (1X binding buffer, 5vol% DMSO) or unlabeled pre-let-7g (1X binding buffer, 
5vol% DMSO) were mixed with 32P-pre-let-7g in 1X binding buffer and incubated at RT for 
30 min. LIN28 (1.5 µM, 1X binding buffer) was added to the negative control (32P-pre-let-
7g), samples (32P-pre-let-7g/small molecules) and positive control 1 (32P-pre-let-7g/unlabeled 
pre-let-7g). The final concentrations in 1X binding buffer were as follows: LIN28 (0.300 
µM), small molecules (20 µM) and unlabeled tpre-let-7g (0.170 µM). DMSO was present at 
1vol% in all reactions. Total volume of each reaction well was 20 µL. All mixtures were 
incubated at RT for 45 min. Glycerol (2.5 vol%) was added to each mixture and protein/RNA 
band shifts were observed by non-denaturing PAGE and visualized by phosphorimager. Band 
intensities were quantified using ImageQuant™ software (GE Healthcare) and used to 
calculate the average proportion of complex formed. 
Dicer processing assay  
In vitro Dicer processing reactions were performed in a similar manner to that described 
previously(9). The Dicer cleavage reaction and non-cleaved control consisted of 32P-pre-let-7g, 
1X Dicer buffer (75 mM NaCl, 20 mM Tris-HCl pH 7.5, 3 mM MgCl2) and in the case of the 
former recombinant Dicer (0.1 units, Invitrogen). For the LIN28 inhibition assay, 32P-pre-let-
7g was pre-incubated with either the corresponding small molecule (1vol% DMSO) or DMSO 
alone (1vol%) in 1X Dicer buffer at RT for 30 min. To these two resulting solutions Lin28 
was added and incubated at RT for 45 min. On addition of recombinant Dicer, the reaction 
mixtures were heated at 37 °C for 5 min. The final concentrations in 1X Dicer buffer are as 
follows: LIN28 (0.350 µM) and small molecules (20 µM). DMSO was present at 1vol% in all 
reactions. Digested products were resolved by denaturing PAGE sequencing gel and 
visualized by phosphorimager. Cleavage bands were quantified using ImageQuant™ software 
(GE Healthcare). For quantification of the data ‘relative Dicer processing efficiency’ was 
 used, which is defined as the product intensity divided by total intensity (products and full-
length substrate). 
Statistical Analysis 
For Kd determination, samples were prepared as described in Small molecule screening 
protocol with a range of compound concentrations. Data was fitted by prism to a hyperbolic 
curve, fitting to a Hill1 equation. Z-factors for individual screening plates were calculated as 
1–3(σp+σn)/(µp-µn), where σ is the standard deviation, µ is the mean, p is positive control 1 
(FAUtpre-let-7g/unlabeled tpre-let-7g/Lin28), and n is negative control (FAUtpre-let-
7g/Lin28). IC50 values were calculated from multiple-point dose-response curves generated 
from three replicates, using nonlinear regression curves (PRISM 5.0, GraphPad Software). 
RESULTS 
To facilitate the identification of small molecule inhibitors of the interaction between pre-
let-7g and Lin28, a fluorescence polarization (FP) based binding assay was first established. 
The principles of the FP assay derive from the ability of rapidly rotating small ligand-bound 
fluorophores, excited by plane polarised light, to depolarise the light emitted. Upon increasing 
the volume of the fluorophore complex (i.e. through protein-ligand binding), the fluorophore 
rotates slower, and as a consequence, a larger proportion of the emitted light remains 
polarised. Monitoring the change in polarised light emitted from the fluorophore upon ligand-
protein complex formation can therefore provide a direct measurement of the fraction of 
ligand bound to the protein. The polarisation value of a sample, P is expressed in 
millipolarisation units (mP), and is defined as the difference in intensity between emitted light 
in the polarisation plane (III) and in the perpendicular plane (IΓ), divided by the total intensity 
of emitted light in both planes (Eq. 1). 
 
 Eq. 1: 
 
As studies to date have implicated the pre-let-7 terminal loop as the main, if not only, 
docking site for Lin289-11, 27, 36-38 a truncated version of pre-let-7g (tpre-let-7g), consisting of 
the pre-let-7g terminal loop with the natural 5' and 3' 5 nt flanking regions, was selected as the 
ligand in this assay. For FP detection, tpre-let-7g was labeled at the 3' end with fluorescein 
(FAUtpre-let-7g) (Figure 1a). The FP of FAUtpre-let-7g was measured in the presence of 
increasing concentrations of N-terminal glutathione S–transferase (GST) tagged-Lin28 
(Lin28)10 over time. The dissociation constant (Kd) of the FAUtpre-let-7g-Lin28 complex at 
equilibrium was 0.33 ± 0.04 µM (Figure 1b). This value is slightly lower than the Kd value we 
and others previously obtained using His tagged-Lin28 and GST tagged-Lin28 and tpre-let-7g 
through gel shift assays in the presence of excess competitor tRNA10, 36. To confirm that the 
change in P of FAUtpre-let-7g observed in the presence of Lin28 (0.33 µM, ∆mP, ~50 mP) 
was due to a direct interaction between Lin28 and tpre-let-7g and not due to indirect effects, 
several control experiments were conducted. The FP signal of FAUtpre-let-7g and fluorescein 
was not altered in the presence of glutathione S–transferase (GST) and Lin28, respectively 
(Supplementary Figure 1a & 1b). Furthermore, no significant change in the intensity of 
FAUtpre-let-7g on addition of Lin28 was detected (Supplementary Figure 1c). Unlabeled 
tpre-let-7g, used as a specific competitor, successfully depleted the ∆mP. On addition of 1X 
and 10X unlabeled tpre-let-7g relative to the concentration of FAUtpre-let-7g, ∆mP reduced 
by ~50 and 100% respectively (Supplementary Figure 2), confirming that the system is 
responsive to specific competitors. In contrast, a much larger excess (50X) of a C/A 
tpre-let-7g mutant (reported to display reduced LIN28 binding more than 8-fold relative to the 
wild-type36) was required to induce a ~100% reduction in the ∆mP (Supplementary Figure 2). 
 Furthermore, a large excess of total yeast RNA (1000X), a non-specific competitor, was also 
required to induce a ~100% reduction in the ∆mP (Supplementary Figure 2). This data 
confirms that the ∆mP observed is due to specific interactions between tpre-let-7g and Lin28. 
As DMSO would be used to prepare stock solutions of candidate inhibitors, an additional 
factor that needed to be considered was the effect of DMSO on the ∆mP. DMSO 
concentrations up to 1% (v/v) had no effect on the ∆mP, however at DMSO concentrations of 
≥2% (v/v) significant variations in the ∆mP were observed (Supplementary Figure 3). A final 
DMSO concentration of 1% (v/v) was selected for screening. The Z' factor39 was used to 
evaluate the quality and robustness of the assay and to assess its suitability for high-
throughput screening. A calculated Z' greater than 0.5 was consistently detected, confirming 
that the assay was robust. Of note, potential stochastic false positive hits were observed, but 
only to a minor extent (2%). As standard in drug discovery protocols, identification of such 
stochastic false positives through hit repetition was crucial to reduce the number of false 
positives prior to the hit validation stages. 
The small molecule library to be tested was obtained from two main sources; the Sigma 
LOPAC1280 library (1280 compounds) and the NCI diversity set II (1356 compounds). In 
addition, a small subset of ligands (132 compounds) designed to specifically target nucleic 
acid structures (laboratory of Prof. Shankar Balasubramanian) were also included in the study, 
bringing the total number of small molecules to 2768. To validate the assay for high 
throughput screening (HTS), a test screen was performed using a 280 compound sub-set of 
the library, each at a final concentration of 20 µM. The data from repeat 1 and repeat 2 were 
each converted to fraction inhibition values relative to the positive and negative controls. To 
investigate the reproducibility of the small molecule screening platform, the data from repeat 
1 was plotted against the data from repeat 2 (Figure 2). A hit was defined as a compound that 
decreased the ∆mP by ≥50%. The majority of the compounds were reproducibly inactive as 
demonstrated by the large number of points clustered around the zero inhibition value. Five 
 hits were shown to be reproducible (Figure 2, circles). The irreproducible hits (Figure 2, 
squares) are likely stochastic false positives, as noted earlier during the assay development 
stage. The preliminary small molecule screen had a 1.8% hit rate, which is in the upper range 
of standard HTS hit rates40, 41. The conditions of the assay were adequate for high-throughput 
small molecule screening.  
In the full-scale screen, 2768 small molecules were tested once at a final concentration of 
20 µM (Figure 3a). As found in the test screen, the majority of the small molecules were 
inactive as demonstrated by the large number of points clustered at the zero inhibition region. 
64 primary hits were identified from the full screen, which equates to a 2.3% hit rate. Small 
molecules can alter the polarisation value without inhibiting the FAUtpre-let-7g-Lin28 
interaction. Common causes of such false positives are the use of intrinsically fluorescent 
compounds, moieties that induce static or dynamic fluorophore quenching, as well as light 
scattering due to compound precipitation. Several small molecules increased the polarisation 
above that of the negative control. This resulted in a fraction inhibition that was lower than 
zero (Figure 3a), and suggests that the molecules are causing complex aggregation, hence 
increasing its molecular weight or that the compound was precipitating out of solution 
(compound precipitation produces scattered light which is highly polarised). Furthermore, a 
number of small molecules in this screen reduced the polarisation to a value lower than that 
observed for the positive control (Figure 3a). This resulted in a calculated fraction inhibition 
that was greater than 1 and suggested that these small molecules interfere with the 
fluorescence of the fluorescein label of FAUtpre-let-7g, lowering the baseline polarisation 
value. Changes in fluorescence upon compound addition can be indicative of the 
aforementioned false positives. To help identify such false positives, the fold intensity change 
of each sample well was calculated, and plotted against its fraction inhibition (Figure 3b). The 
fold intensity change equates to the total fluorescence intensity of the sample well normalized 
to the averaged total fluorescence intensity of the control wells. The plot of the fold intensity 
 change versus fraction inhibition revealed several likely false positives. These compounds 
were shown to either increase the total intensity of the well by >5-fold or severely quench the 
fluorescence to <0.1 (Figure 3b). These compounds were removed from the primary hits. A 
hit repetition stage was then applied to assess the reproducibility of the primary hits and in 
particular, identify stochastic false positives. A total of 44 primary hits were retested and the 
fraction inhibition displayed by each of these compounds is shown in Figure 4. A shortlist of 
21 small molecules, equivalent to a final hit rate of 0.75%, which is in the range of previously 
reported values40, 41, were shown to reproducibly decrease the ∆mP by ≥50% (secondary hits).  
Next, it was crucial to validate the secondary hits against the full-length pre-let-7g, as well 
as to confirm their activity in an alternative, preferably non-fluorescent, biochemical assay. 
To fulfil both of these criteria, the secondary hits were tested (at 20 μM concentration) in a 
radioactivity based EMSA against the interaction between 32P-labeled full-length pre-let-7g 
([32P]-pre-let-7g) and Lin28. Unlike our previous work10, this assay was performed in the 
absence of competitor RNA; here the lower stoichiometric Lin28-pre-let-7 complexes can be 
observed13. As several of the secondary hits were from the same family of compounds, one 
representative compound from each family was chosen for the EMSA validation. Of the 21 
secondary hits, a total of 15 were tested and the fraction inhibition for each secondary hit 
calculated. The attrition rate in the EMSA assay was high (see discussion) with only four 
compounds confirmed as true positives that inhibit the interaction between [32P]-pre-let-7g 
and Lin28 by ≥50% (Figure 5a: compare lanes 2 & 10 to lane 6; Figure 5b: compare lanes 2 & 
11 to lanes 5, 6 and 9, Figure 5c). These compounds, referred to as validated hits 4, 10, 11 and 
14, were identified as Aurintricarboxylic acid, 6-Hydroxy-DL-DOPA, Reactive Blue 2 and 
SB/ZW/0065, respectively (Figure 6). The effect of one secondary hit, SB/SM/0117 (Figure 
6: secondary hit 15) was not detectable via this method as the amount of radioactivity and the 
mobility of the radioactivity through the gel matrix were greatly reduced relative to that of the 
negative control (Figure 5b: compare lanes 2 and 10). This suggested that SB/SM/0117 was 
 precipitating out of solution, and this hit was therefore removed from the validated hit 
collection. 
For additional studies, the validated hits were re-purchased or re-synthesised. All validated 
hits were again shown to inhibit the interaction between Lin28 and pre-let-7g at a 
concentration of 20 µM in the FP assay. As reactive Blue 2 is no longer commercially 
available, a closely related analogue that contained a very similar core structure to Reactive 
Blue 2, but lacked the aniline substituent on the triazine was purchased. The replacement was 
referred to as 11b (Figure 6). The half maximal inhibitory concentration (IC50) value for each 
validated hit was calculated from a plot of concentration versus ∆mp. All validated hits 
displayed a dose-dependent inhibition of the Lin28-tpre-let-7 interaction. The IC50 values 
calculated for Aurintricarboxylic acid, 6-hydroxy DL-DOPA, Reactive Blue 4 and 
SB/ZW/0065 were 1.18 ± 0.23 μM, 7.05 ± 0.13 μM, 10.75 ± 0.1 μM and 4.71 ± 0.16 μM, 
respectively (Supplementary Figure 4). Compounds SB/ZW/0065, Aurintricarboxylic acid, 6-
hydroxy DL-DOPA and Reactive Blue 4 were carried forward to the in vitro based functional 
validation assay. In addition, SB/ZW/0062, a closely related analogue of SB/ZW/0065, which 
was also identified as a secondary hit but not tested in the EMSA, was also taken forward 
(Figure 6, referred to as 14b).  
To assess whether the validated hits could prevent the Lin28-mediated inhibition of let-7g 
biogenesis, the effect of these compounds on Lin28 blockage of pre-let-7g cleavage by Dicer 
was assessed through an in vitro Dicer processing assay10. In the presence of Dicer we 
observed a reduction in the amount of pre-let-7g, and the appearance of an approximately 20 
nt band, corresponding to the mature let-7g (Figure 7a, compare lane 1 and lane 2). Upon 
addition of Lin28, the intensity of the mature let-7g band reduced, and that of the pre-let-7g 
band increased (Figure 7a, compare lane 2 & lane 3, Figure 7b) confirming Lin28 inhibition 
of Dicer processing of pre-let-7g in vitro. The effect of the validated hits upon this Lin28-
mediated block in pre-let-7g processing varied greatly. It was noteworthy that one of the 
 validated hits, 6-hydroxy DL-DOPA (validated hit 10), restored Dicer processing of pre-let-7g 
to the level observed by Dicer alone (Figure 7a, compare lane 1 to lane 2), in the presence of 
Lin28 (Figure 7a, compare lane 2 and 3 to lane 7, Figure 7b). In addition, a second compound, 
SB/ZW/0065 (validated hit 14), also partially restored Dicer processing, in the presence of 
Lin28 (Figure 7a, compare lanes 2 and 3 to lane 4, Figure 7b). However, in contrast, 
Aurintricarboxylic acid (validated hit 4) and, to a lesser degree, SB/ZW/0062 (validated hit 
14b) and Reactive Blue 4 (validated hit 11b) inhibited Dicer processing beyond that observed 
in the presence of Lin28 (Figure 7a, compare lanes 2 and 3 to lanes 5, 6 & 8, Figure 7b). For 
6-hydroxy DL-DOPA (validated hit 10), the observed enhance in Dicer processing in the 
presence of Lin28 was dose dependent (Supplementary Figure 5a) and was not observed in 
the absence of Lin28 (Supplementary Figure 5b). This confirms that the increase in Dicer 
processing of pre-let-7g by 6-hydroxy DL-DOPA is due to inhibition of the Lin28-pre-let-7g 
interaction.   
DISCUSSION 
A fluorescence polarization based in vitro assay was established and exploited to identify 
small molecules capable of inhibiting the direct interaction between Lin28 and a truncated 
form of pre-let-7g (tpre-let-7g). Using this approach, a library of 2768 pharmacologically 
active small molecules (including FDA approved drugs) was screened and molecules that 
successfully prevented binding of Lin28 to tpre-let-7g were revealed. Several of these 
molecules were subsequently validated as inhibitors of the interaction between Lin28 and full-
length pre-let-7g in an alternate biochemical assay. Remarkably, two of the active entities also 
prevented the Lin28-mediated inhibition of Dicer processing of pre-let-7g in vitro, validating 
the screening approach. These two promising compounds were the dopamine precursor, 6-
hydroxy DL-DOPA and the benzo[a]phenoxazine derivative SB/ZW/0065, a novel compound 
synthesized in the Balasubramanian laboratory42. Of interest, numerous structural analogues 
 of SB/ZW/0065 (12) and 6-hydroxy DL-DOPA (five) were inactive in the FP screen 
(Supplementary Figure 6 & 7), suggesting that specific interactions independent from their 
shared structural scaffold are crucial for their activity. Interestingly, oxidopamine 
hydrochloride, an untested analogue of 6-hydroxy DL-DOPA, has been previously identified 
as a potent small molecule inhibitor of the loading of miRNAs into the RISC complex in 
cells. Furthermore aurintricarboxylic acid, a known inhibitor of RNA-protein interactions, 
which profoundly inhibited Dicer in our study, was also active in this study43. Of note, no 
change in thermal melting and/or RNase foot-prints of pre-let-7g was observed in the 
presence of 6-hydroxy DL-DOPA and SB/ZW/0065 at compound concentrations of up to 30 
µM, suggesting that these compounds are not binding directly to pre-let-7g (data not shown). 
The effects of 6-hydroxy DL-DOPA and SB/ZW/0065 on let-7g levels in Lin28 expressing 
P19 embryonal carcinoma cells were also assessed. SB/ZW/0065 and 6-hydroxy DL-DOPA 
had no significant effect on let-7g levels in this cell system (data not shown).   
The attrition rate in the EMSA was unexpectedly high. On evaluation of the FP fraction 
inhibition and background intensities of the 15 secondary hits, all four validated hits displayed 
a fraction inhibition between 0.5 and 1.1 and additionally altered the background fluorescence 
intensity ≤2-fold. Conversely, the majority of the remaining secondary hits (82%) displayed 
fraction inhibitions >1.1 and/or altered the background fluorescence intensity >2-fold. This 
suggests that the criteria applied to select hits for EMSA validation (fraction inhibition ≥0.5; 
background intensity change ≤5-fold) were not sufficiently stringent. For future screening 
applications a more focused selection process should be considered.  
In conclusion, we have identified inhibitors of the interaction between Lin28 and pre-let-7g. 
Two small molecules capable of inhibiting the interaction between Lin28 and pre-let-7g, and 
consequently able to restore Dicer-mediated cleavage of pre-let-7g in the presence of the 
inhibitor Lin28, were found. This study provides biophysical and biochemical proof of 
concept for the small molecule enhancement of Dicer processing of pre-let-7g. Furthermore, it 
 presents an alternate screening approach to those recently reported by Roos et al44 and Lin et 
al45 for identification of small molecule inhibitors of the Lin28-pre-let-7-TUTase system. The 
overall design of this study could be utilized as a basis to identify small molecule inhibitors of 
this interaction (inclusive of other members of the let-7 family), or other RNA targets of 
Lin28.  
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 FIGURE LEGENDS 
Figure 1. Assay Development. a. Structure of FAUtpre-let-7g. b. The change in fluorescence 
polarisation of 0.017 µM FAUtpre-let-7g in the presence of increasing concentrations of 
Lin28 was quantified from three independent experiments and represented as the average 
fraction of Lin28-bound FAUtpre-let-7g. Data was fitted by prism to a hyperbolic curve, 
fitting to a Hill1 equation and the dissociation constant was calculated (Kd). 
Figure 2. Test screen. The fraction inhibitions observed for each small molecule from repeat 1 
and repeat 2 of a test screen of 280 small molecules in the fluorescence polarization assay. 
The five most highly reproducible hits (≥50% inhibition) are circled. Likely false positives are 
in squares.  
Figure 3. Full small molecule screen. a. The fraction inhibition observed for each compound 
from a full screen of 2768 compounds in the fluorescence polarization assay. Primary hits are 
located above the dashed line (>50% inhibition). b. A plot of the fold intensity change 
(normalised to the control wells) versus the fraction inhibition for each compound. Potential 
false positives are circled. Expanded image below.  
Figure 4. Hit repetition. The average fraction inhibition observed on repetition of 44 primary 
hits in the fluorescence polarization assay. A secondary hit was defined as a small molecule 
that reproducibly displayed a fraction inhibition value greater than 0.5.  
Figure 5. Validation of the secondary hits against the interaction between [32P]-pre-let-7g and 
Lin28 by EMSA. a. & b. Representative EMSAs performed with [32P]-pre-let-7g, Lin28 
(0.300 μM) and secondary hits (20 μM). Addition of unlabeled pre-let-7g (10x) to the Lin28-
[32P]-pre-let-7g binding reaction was used as the positive control, and Lin28-[32P]-pre-let-7g 
binding reaction as the negative control. c. Band intensities were quantified using 
ImageQuant™ and the fraction bound was calculated relative to the signals in the positive and 
 the negative control lanes. C: negative control. Error bars represent the standard deviation of 
two independent experiments. 
Figure 6. In vitro validated inhibitors of the interaction between pre-let-7g and Lin28. The un-
validated secondary hit 15 is also shown.  
Figure 7. Activity of the validated hits against the Lin28-mediated inhibition of pre-let-7g 
processing by Dicer. a. Representative autoradiogram of the Dicer processing assay of [32P]-
pre-let-7g in the presence of Lin28 and the validated hits (20 μM). *: initial Dicer cleavage 
product (single cleavage). b. Relative Dicer processing efficiency. Results were normalized 
relative to the Dicer processing efficiency obtained for [32P]-pre-let-7g  alone (positive 
control, lane 1) and in the presence of Lin28 (negative control, lane 2). Error bars represent 
the standard deviation of two independent experiments. 
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